Amylyx Pharmaceuticals (NASDAQ: AMLX) investors approve directors, auditor and say-on-pay

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Amylyx Pharmaceuticals (AMLX) stockholders decide about Class II directors?

Did Amylyx Pharmaceuticals (AMLX) stockholders approve the company’s auditor for 2026?

How did Amylyx Pharmaceuticals (AMLX) stockholders vote on executive compensation?

Were there any other matters voted on at the Amylyx (AMLX) 2026 annual meeting?

When was the Amylyx Pharmaceuticals (AMLX) 2026 annual stockholder meeting held?

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Amylyx Pharmaceuticals, Inc. reported the results of its annual stockholder meeting. Stockholders elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors to serve until the 2029 annual meeting, with each nominee receiving more than 76 million votes for.

Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,036,295 votes for and minimal opposition. In a non-binding advisory vote, stockholders approved the compensation of the company’s named executive officers, with 77,534,824 votes for and 13,490,653 against.

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Votes for Milne: 76,937,972 votes Votes for Fonteyne: 86,275,670 votes Auditor ratification support: 102,036,295 votes for +3 more

6 metrics

Votes for Milne 76,937,972 votes Election of George Mclean Milne Jr., Ph.D. as Class II director

Votes for Fonteyne 86,275,670 votes Election of Paul Fonteyne as Class II director

Auditor ratification support 102,036,295 votes for Ratification of Deloitte & Touche LLP for fiscal year ending December 31, 2026

Auditor votes against 34,484 votes against Ratification of Deloitte & Touche LLP

Say-on-pay votes for 77,534,824 votes for Non-binding advisory vote on named executive officer compensation

Say-on-pay votes against 13,490,653 votes against Non-binding advisory vote on named executive officer compensation

Broker Non-Votes, independent registered public accounting firm, non-binding, advisory basis, Emerging growth company, +1 more

5 terms

Broker Non-Votes financial

"Votes For | | | 76,937,972 | | | | 14,108,630 | | | | 11,029,810 |"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm regulatory

"ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

non-binding, advisory basis regulatory

"approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"

A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Annual Meeting of Stockholders financial

"held its Annual Meeting of Stockholders on June 4, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/04/2026 - 04:06 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2026

AMYLYX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41199

46-4600503

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


55 Cambridge Parkway, Suite 6W Cambridge, MA		02142
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 682-0917

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	AMLX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

Amylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 4, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 23, 2026. The final voting results are set forth below.

Proposal 1 – Election of Class II Directors

The stockholders of the Company elected each of George Mclean Milne Jr., Ph.D. and Paul Fonteyne as a Class II director of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 or until their successor has been duly elected and qualified or until such director’s earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows:


Name	Votes For		Votes Withheld		Broker Non-Votes
George Mclean Milne Jr., Ph.D.		76,937,972		14,108,630		11,029,810
Paul Fonteyne		86,275,670		4,770,932		11,029,810

Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:


Votes For	Votes Against	Abstain	Broker Non-Votes
102,036,295	34,484	5,633	0

Proposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company’s Named Executive Officers

The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers . The results of the stockholders’ vote with respect to such approval were as follows:


Votes For	Votes Against	Abstain	Broker Non-Votes
77,534,824	13,490,653	21,125	11,029,810

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Stockholders elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors. They will serve three-year terms ending at the 2029 annual meeting, receiving 76,937,972 and 86,275,670 votes for, respectively, with additional votes withheld and broker non-votes recorded.

Yes, stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for 2026. The vote was 102,036,295 for, 34,484 against, and 5,633 abstentions, with no broker non-votes, indicating broad support for the auditor selection.

Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers. The proposal received 77,534,824 votes for, 13,490,653 against, 21,125 abstentions, and 11,029,810 broker non-votes, reflecting support but with a meaningful number of opposing votes.

No, stockholders considered only three proposals: election of two Class II directors, ratification of Deloitte & Touche LLP as auditor for 2026, and a non-binding advisory vote on executive compensation. The filing states no other matters were submitted or voted on.

The annual stockholder meeting was held on June 4, 2026. At this meeting, stockholders voted on electing two Class II directors, ratifying Deloitte & Touche LLP as auditor for 2026, and approving, on an advisory basis, executive compensation for named officers.

AMYLYX PHARMACEUTICALS, INC.

Date: June 4, 2026

/s/ James M. Frates

James M. Frates

Chief Financial Officer

3 documents